ArticleNanotechnology, science and applications2025
An Approach to Enhance the Solubility of an Atypical Antipsychotic Drug, Aripiprazole: Design, Characterization, and Evaluation of Arabinoxylan-Based Nanoparticles.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nano Engineered Chitosan-Based Delivery System for Vonoprazan Fumarate for Enhanced Bioavailability: Fabrication and Evaluation.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Natural polymers have emerged as versatile and sustainable alternatives to synthetic polymers in pharmaceutical and biomedical applications. This study focuses on the extraction of arabinoxylan (AX) from maize husk and its potential as a promising excipient to enhance the solubility and oral bioavailability of Aripiprazole (APZ), a poorly water-soluble antipsychotic drug, offering a robust strategy for overcoming challenges associated with hydrophobic drugs. Methods: APZ-loaded AX nanoparticles were synthesized using the ionotropic gelation technique. The formulation with the highest encapsulation efficiency designated as FN4 was selected for detailed characterization. Various analytical techniques, including Scanning Electron Microscopy (SEM), X-ray Diffraction (XRD), and Differential Scanning Calorimetry (DSC), were employed to assess the morphological, crystalline, and thermal properties of the nanoparticles. In vitro release studies were conducted on both simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8) to evaluate drug dissolution behaviour. The everted sac method was utilized to assess the permeation and transport of APZ from the AX-based nanoparticles. Results: The FN4 formulation exhibited an encapsulation efficiency of 88.9% ± 1.77%, with a particle size of 284.4 nm, a polydispersity index (PDI) of 0.346, and a zeta potential of 20.7 mV. SEM analysis revealed a uniform distribution of polyhedral-shaped nanoparticles. XRD and DSC analyses indicated that APZ was in an amorphous state within the nanoparticles. Drug release was more pronounced at pH 6.8, with the AX nanoparticles showing sustained release. The everted sac method demonstrated enhanced permeation of APZ across intestinal membranes, supporting the potential of AX nanoparticles in improving drug absorption. Discussion: The AX-based nanoparticle formulation significantly improved the solubility, pH-dependent release profile, and sustained release of APZ, offering a promising strategy to enhance the oral bioavailability of poorly soluble drugs. These findings suggest that AX nanoparticles could serve as an effective delivery system for enhancing the therapeutic potential of hydrophobic drugs like APZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.